What’s the main difference between Synjardy and Jardiance?
Jardiance is the brand name for empagliflozin, a medication in the SGLT2 inhibitor class that helps lower blood sugar and can reduce cardiovascular and kidney risks in certain patients.
Synjardy is a combination product. It contains empagliflozin plus metformin, so it treats blood sugar using both drugs in one pill (empagliflozin + metformin).
So, the simplest way to think about it: Jardiance = empagliflozin alone; Synjardy = empagliflozin + metformin.
How do they compare for type 2 diabetes use?
Because Synjardy adds metformin, it’s often chosen when a person with type 2 diabetes needs both:
- an SGLT2 inhibitor effect (from empagliflozin), and
- a metformin effect (from metformin).
If someone only needs the SGLT2 inhibitor part (or can’t take metformin), Jardiance may be the fit instead.
Do they have the same heart and kidney benefits?
Both products include empagliflozin, so they share the empagliflozin-related benefits for eligible patients (such as reducing risks of cardiovascular events and slowing certain kidney disease progression). The metformin component in Synjardy doesn’t change the fact that empagliflozin is doing the SGLT2 portion of those effects.
What side effects are patients most likely to notice?
Both will have typical SGLT2-inhibitor risks because both include empagliflozin, such as genital yeast infections and urinary tract infections. They can also cause more frequent urination and changes in volume status (dehydration/low blood pressure risk in some people).
Synjardy can add metformin-specific side effects, classically gastrointestinal effects (like nausea, diarrhea, or abdominal discomfort). This is one reason some patients tolerate Jardiance better if metformin doesn’t agree with them.
How do dosing and pill burden typically differ?
Jardiance is empagliflozin-only. Synjardy combines empagliflozin with metformin, which can reduce pill burden compared with taking Jardiance plus metformin separately, but the exact regimen depends on the specific Synjardy strength prescribed.
Which one is usually chosen first?
Clinicians often consider:
- Jardiance when the goal is the SGLT2 inhibitor therapy and metformin isn’t needed or isn’t appropriate.
- Synjardy when both empagliflozin and metformin are intended therapy and simplifying treatment is helpful.
The best choice depends on kidney function, blood sugar control, other medical conditions, and tolerance of metformin.
Can you switch between them?
In many cases, yes. Patients sometimes switch between Jardiance and Synjardy depending on whether they also need metformin, or whether they’re having side effects. Switching should be done with prescriber guidance because metformin dose and tolerability matter, and kidney function affects safe use of both SGLT2 inhibitors and metformin.
What should patients ask their doctor before choosing?
Common decision points include:
- Kidney function (affects both empagliflozin and metformin eligibility/dosing).
- History of recurrent genital infections or urinary infections.
- Gastrointestinal tolerance (metformin can be limiting).
- Blood pressure or dehydration risk (SGLT2 inhibitors can contribute).
- Current diabetes regimen (to avoid duplication and ensure equivalent empagliflozin exposure).
Sources
No sources were provided in the prompt. If you want, tell me whether you mean the brand products in the US (or another country), and I can give a more precise comparison (strengths, dosing forms, and eligibility rules).